IGI Logo

Strategic AI Pivot Gains Traction despite Temporary Revenue Headwinds

HAPPSTMN delivered a mixed Q4FY26, with FY26 CC revenue growth of 9.2%, marginally below guidance due to delays in large Arttha deal closures and project-specific softness in Hi-Tech and Healthcare. Despite this, BFSI remained resilient and the deal pipeline grew strongly by 27% QoQ, supporting the management’s FY27E guidance of 12.5% CC growth. Margin remained stable at 17.5%, aided by improved utilisation and operational efficiency, though continued AI investments may keep near-term profitability range-bound. We believe execution on AI monetisation, platform scaling-up and margin discipline will remain critical for sustaining growth momentum. Accordingly, we expect Revenue/EBIT/PAT to respectively expand at a CAGR of 16.5%/21.2%/25.6% over FY26–FY29E. While we maintain our ‘BUY’ rating, we revise our target price to INR 560 (earlier INR 620), based on the FY28E EPS

Earnings Miss Expectation; Margin Drags

* HAPPSTMN reported Q4FY26 revenues of INR 6,041 Mn, (vs CIE estimate of INR 6,455 Mn), up 2.8% QoQ and 10.9% YoY. In USD terms it reported degrowth of 1.1% QoQ in revenues at USD 65.0 Mn. For FY26, INR revenues stood at INR 2,315 Mn, up by 12.3% YoY, while the USD revenue stood at USD 265.8 Mn, up 9.1% YoY.

* EBIT Margin came in at 13.6% for Q4FY26, declining 90 bps QoQ (vs CIE estimate of 15.6%). For the full year, EBIT margin stood at 13.6%, up by 70 bps YoY. Utilisation reduced by 60 bps QoQ to 81.4%.

* PAT for the quarter came in at INR 61.2 Mn, up by 51.8% QoQ and 32.5% YoY. For the full year, PAT stood at INR 212.6 Mn, up by 8% YoY. EPS for the quarter came at INR 4.1.

Guidance Reiterated despite Project-specific Headwinds

HAPPSTMN’s FY26 performance came in marginally below its 10% CC growth guidance, with revenue growth at 9.2%, primarily affected by delays in deal closure and revenue recognition of a few large Arttha platform license deals. EdTech showed signs of recovery (+8.2% QoQ), while BFSI remained resilient (+1.9% QoQ). However, Hi-Tech declined sharply (-10.8% QoQ) due to completion and temporary pause of a large client engagement, while Healthcare also saw sequential softness (-5.4% QoQ) following completion of a pharmarelated engagement in Q3. The company reported a strong 27% QoQ increase in deal pipeline and reiterated its FY27 CC growth guidance of 12.5%, while remaining aspirational towards a 15% growth trajectory. We believe that successful monetisation of AI investments, scaling-up platform-led revenues, and sustaining margin discipline will remain key monitorables, going forward.

Margin Sustained amid Continued AI Investments, Guidance Maintained

Q4FY26 operating margin remained stable at 17.5%, supported by improved utilization (81% vs 77.4% YoY), operational efficiency from acquisition integration and favourable forex movements. These benefits were partly offset by currency losses on forward contracts and continued investments in AI capabilities, platforms and sales expansion. The management expects margin to improve by ~100 bps over time, targeting an operating margin range of 17.5%–18.5%

For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer
SEBI Registration no.: INZ 000160131